About The Study: The findings of this randomized clinical trial including 2,200 adolescents indicate that the NVX-CoV2373 (Novavax, Inc.) COVID-19 vaccine is safe, immunogenic, and efficacious in preventing COVID-19, including the predominant Delta variant, in adolescents.
Authors: German Anez, M.D., of Novavax, Inc., in Gaithersburg, Maryland, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2023.9135)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.9135?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=042623
About JAMA Network Open : JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
JAMA Network Open